

Appendix G Funded rates of MRFF grant opportunities opened between 7 November 2020 and 5 November 2022

Table G Funded rates of MRFF grant opportunities

| MRFF initiative | Grant opportunity | Applications | Applications funded | Funded rate |
|---|--|---|---------------------|-------------|
| Australian Brain Cancer Mission | 2021 Brain Cancer Research | 14 | 3 | 21.4% |
| | 2021 GBM AGILE | This grant opportunity was withdrawn. | | |
| | 2022 Australian Brain Cancer Research Infrastructure | 2 | 1 | 50% |
| Cardiovascular Health Mission | 2020 Cardiovascular Health | 75 | 16 | 21.3% |
| | 2021 Cardiovascular Health | 100 | 41 | 41.0% |
| | 2022 Cardiovascular Health | 51 | 14 | 27.5% |
| Clinical Trials Activity | 2021 Clinical Trials Activity | 105 | 31 | 29.5% |
| | 2021 Innovative Therapies for Mental Illness | 16 | 7 | 43.8% |
| | 2021 International Clinical Trial Collaborations (Round 21.1) | 24 | 4 | 16.7% |
| | 2021 International Clinical Trial Collaborations (Round 21.2) | 24 | 3 | 12.5% |
| | 2021 Rare Cancers, Rare Diseases and Unmet Need | 97 | 29 | 29.9% |
| | 2022 International Clinical Trial Collaborations (Round 22.1) | 20 | 3 | 15% |
| | 2022 International Clinical Trial Collaborations (Round 22.2) | No outcome available at the time this report was written. | | |
| Clinical Trials Activity and Emerging Priorities and Consumer-Driven Research | 2022 Multiple Sclerosis Research | No outcome available at the time this report was written. | | |
| | 2022 Pancreatic Cancer Research | 9 | 4 | 44.4% |
| Clinician Researchers | 2020 Clinician Researchers: Applied Research in Health | 181 | 14 | 7.7% |
| | 2022 Clinician Researchers: Nurses, Midwives and Allied Health | 124 | 15 | 12.1% |
| Coronavirus Research Response | 2021 COVID-19 Vaccine-Associated Thrombosis with Thrombocytopenia Syndrome | 1 | 1 | 100% |
| | 2021 COVID-19 Health Impacts and Vaccination Schedules | 26 | 5 | 19.2% |

| | | | | |
|--|---|---|----|-------|
| | 2021 COVID-19 Treatment Access and Public Health Activities | 31 | 14 | 45.2% |
| Dementia, Ageing and Aged Care Mission | 2020 Dementia, Ageing and Aged Care | 60 | 11 | 18.3% |
| | 2021 Dementia, Ageing and Aged Care | 55 | 18 | 32.7% |
| | 2022 Dementia, Ageing and Aged Care | 36 | 15 | 41.7% |
| Early to Mid-Career Researchers | 2021 Early to Mid-Career Researchers | 428 | 23 | 5.4% |
| Emerging Priorities and Consumer-Driven Research | 2020 Improving Diagnosis in Cancers With Low Survival Rates | 20 | 8 | 40.0% |
| | 2020 Neurofibromatosis Research | 9 | 4 | 44.4% |
| | 2020 Paediatric Cancer | 1 | 1 | 100% |
| | 2021 Chronic Musculoskeletal Conditions in Children and Adolescents | 28 | 11 | 39.3% |
| | 2021 Chronic Neurological Conditions | 16 | 8 | 50.0% |
| | 2021 Improving the Health and Wellbeing of Aboriginal and Torres Strait Islander Mothers and Babies | 19 | 5 | 26.3% |
| | 2022 Mitochondrial Donation Pilot Program | 3 | 1 | 33.3% |
| Genomics Health Futures Mission | 2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care | 25 | 10 | 40.0% |
| | 2020 Genomics Health Futures Mission | 41 | 17 | 41.5% |
| | 2021 Genomics Health Futures Mission | 41 | 20 | 48.8% |
| | 2022 Genomics Health Futures | No outcome available at the time this report was written. | | |
| Indigenous Health Research Fund | 2020 Indigenous Health Research | 20 | 6 | 30.0% |
| | 2021 Indigenous Health Research | 22 | 11 | 50.0% |
| | 2022 Indigenous Health Research | No outcome available at the time this report was written. | | |
| Medical Research Commercialisation | 2020 Early Stage Translation and Commercialisation Support | 12 | 4 | 33.3% |
| | 2021 BioMedTech Incubator | 5 | 1 | 20% |
| National Critical Research Infrastructure | 2021 mRNA Clinical Trials Enabling Infrastructure | 7 | 5 | 71.4% |
| | 2022 National Critical Research Infrastructure | 142 | 19 | 13.4% |

| | | | | |
|--|---|---|----|-------|
| | 2020 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists | 53 | 5 | 9.4% |
| | 2021 Chronic Respiratory Conditions | 33 | 10 | 30.3% |
| | 2021 Consumer-Led Research | 102 | 14 | 13.7% |
| Preventive and Public Health Research | 2021 Maternal Health and Healthy Lifestyles | 29 | 11 | 37.9% |
| | 2021 Optimising the Clinical Use of Immunoglobulins | 4 | 4 | 100% |
| | 2022 Assessment of High-Cost Gene Treatments and Digital Health Interventions | No outcome available at the time this report was written | | |
| | 2022 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists | 19 | 10 | 52.6% |
| Preventive and Public Health Research and Emerging Priorities and Consumer-Driven Research | 2022 Effective Treatments and Therapies | 33 | 16 | 48.5% |
| Primary Health Care Research | 2021 Primary Health Care Digital Innovations | 36 | 6 | 16.7% |
| | 2021 Primary Health Care Research | 25 | 4 | 16.0% |
| Rapid Applied Research Translation | 2020 Rapid Applied Research Translation | 72 | 9 | 12.5% |
| | 2020 Primary Health Care Research Data Infrastructure | 34 | 7 | 20.6% |
| Research Data Infrastructure | 2021 Research Data Infrastructure | 92 | 5 | 5.4% |
| | 2022 Research Data Infrastructure | No outcome available at the time this report was written. | | |
| | 2020 Stem Cell Therapies Mission | 59 | 17 | 28.8% |
| Stem Cell Therapies Mission | 2021 Stem Cell Therapies | 27 | 7 | 25.9% |
| | 2022 Stem Cell Therapies | 44 | 13 | 29.5% |
| Traumatic Brain Injury Mission | 2020 Traumatic Brain Injury Mission | 26 | 8 | 30.8% |
| Traumatic Brain Injury Mission and Emerging Priorities and Consumer-Driven Research | 2021 Traumatic Brain Injury | 11 | 2 | 18.2% |

Table represents the subset of grant opportunities open and assessed between November 2020 to data available at the time this report was written. Applications funded includes projects that are not listed in Appendix E as payment commenced outside the period between 7 November 2020 and 5 November 2022. The grant recipients are listed on the [MRFF website](#).